NCT03288753

Brief Summary

The present study aims to evaluate patient satisfaction and audiological performance with their current cochlear implant speech processor, the Neuro 1, and to compare it with the satisfaction and performance obtained with the new speech processor, the Neuro 2.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
98

participants targeted

Target at P50-P75 for not_applicable

Timeline
Completed

Started Oct 2017

Geographic Reach
1 country

9 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 18, 2017

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 20, 2017

Completed
12 days until next milestone

Study Start

First participant enrolled

October 2, 2017

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 11, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 11, 2019

Completed
Last Updated

March 23, 2023

Status Verified

March 1, 2023

Enrollment Period

1.3 years

First QC Date

September 18, 2017

Last Update Submit

March 22, 2023

Conditions

Keywords

Cochlear implant

Outcome Measures

Primary Outcomes (1)

  • Satisfaction questionnaire

    The listener has to rate his appreciation of the Neuro 1 and Neuro 2 device and the sound quality on 7 points scale. The outcome measure corresponds to averaged score. The questionnaire has been developed by Oticon Medical to investigate satisfaction patient for their current and future speech processors. This questionnaire is not validated in the literature.

    15 minutes

Secondary Outcomes (3)

  • Speech comprehension in quiet

    15 mins

  • Speech comprehension in Noise

    15 mins

  • French Quick Sin

    5 mins

Study Arms (2)

Adults and children above 14 years old

EXPERIMENTAL

Visit 1: Satisfaction questionnaire on Neuro 1 Speech intelligibility in quiet on Neuro 1 Speech intelligibility in noise on Neuro 1 VRB (Vocale Rapide dans le Bruit) on Neuro 1 Visit 2 (15 days after V1): Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2 Visit 3 (3 months after V2): Satisfaction questionnaire on Neuro 2 Speech audiometry in quiet on Neuro 2 Speech audiometry in noise on Neuro 2 VRB (Vocale Rapide dans le Bruit) on Neuro 2

Other: Satisfaction questionnaireBehavioral: Speech intelligibility in quietBehavioral: Speech intelligibility in noiseBehavioral: VRB (Vocale Rapide dans le Bruit)

children up to 14 years old

EXPERIMENTAL

Visit 1 Satisfaction questionnaire on Neuro 1 Visit 2 (15 days after V1): Satisfaction questionnaire on Neuro 2 Visit 3 (3 months after V2): Satisfaction questionnaire on Neuro 2 The questionnaires have to be filled in by the parents. The child can participate in the completion of the questionnaire if he is willing and understands the questions.

Other: Satisfaction questionnaire

Interventions

Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.

Adults and children above 14 years oldchildren up to 14 years old

The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.

Adults and children above 14 years old

The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. The noise corresponds to a cocktail party presented at +10 dB SNR (Speech on Noise Ratio). At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.

Adults and children above 14 years old

Speech intelligibility in noise measured with the test VRB (Vocale Rapide dans le Bruit, French version of the Quick Sin). This test measures the SNR (Signal to Noise Ratio) at which the listeners understand half of the words of a sentence correctly. The outcome measure is in dB. 3 lists are presented. Speech signals are presented at 60 dB SPL.

Also known as: french Quick SIN
Adults and children above 14 years old

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

  • informed consent
  • Native French speaker or fluent French speaker
  • Patient already fitted with one or two speech processor Neuro 1 for at least 5 months

You may not qualify if:

  • vulnerable patients, at the exception of children (pregnant women, persons under guardianship)
  • No Social security affiliation
  • non-compliant patient

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (9)

Hôpital Pellegrin

Bordeaux, 33000, France

Location

Hôpital Roger Salengro

Lille, 59037, France

Location

Hôpital Edouard Herriot

Lyon, 69003, France

Location

CHRU de Nancy Hôpital central

Nancy, 54035, France

Location

CHU de Nantes Hôtel-Dieu

Nantes, 44093, France

Location

CHU Nice - Institut Universitaire de la Face et du Cou

Nice, 06103, France

Location

Hôpitaux Pédiatriques de Nice CHU-Lenval

Nice, 06200, France

Location

Hôpital Pitié Salpêtrière - APHP

Paris, 75013, France

Location

Hôpital Necker-Enfants Malades

Paris, 75015, France

Location

MeSH Terms

Conditions

Hearing Loss, Sensorineural

Interventions

Noise

Condition Hierarchy (Ancestors)

Hearing LossHearing DisordersEar DiseasesOtorhinolaryngologic DiseasesSensation DisordersNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and Symptoms

Intervention Hierarchy (Ancestors)

SoundRadiation, NonionizingRadiationPhysical PhenomenaEnvironmentEcological and Environmental PhenomenaBiological PhenomenaEnvironment and Public HealthEnvironmental PollutionPublic Health

Study Officials

  • Christophe Vincent, MD, PROF

    Hôpital Roger Salengro CHRU de Lille

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 18, 2017

First Posted

September 20, 2017

Study Start

October 2, 2017

Primary Completion

January 11, 2019

Study Completion

January 11, 2019

Last Updated

March 23, 2023

Record last verified: 2023-03

Data Sharing

IPD Sharing
Will not share

Locations